调强放疗技术对局部晚期非小细胞肺癌的影响:NRG Oncology RTOG 0617 随机临床试验的二次分析
该研究为 NRG Oncology RTOG 0617 随机临床试验的二次分析,比较调强放疗(IMRT)与三维适形放疗(3D-CRT)在局部晚期非小细胞肺癌中的疗效。中位随访 21.3 个月,482 例患者中 53% 接受 3D-CRT、47% 接受 IMRT。IMRT 组 ≥3 级肺炎发生率更低(3.5% vs 7.9%,P=0.039),校正后风险降低(OR 0.41,95%CI 0.171-0.986,P=0.046);两组 2 年总生存、无进展生存、局部失败及远处转移无差异。
要点
- IMRT 组 ≥3 级肺炎发生率 3.5%,3D-CRT 组 7.9%(P=0.039)。
- 校正分析中 IMRT 与 ≥3 级肺炎风险降低相关(OR 0.41,95%CI 0.171-0.986,P=0.046)。
- 两组 2 年总生存、无进展生存、局部失败及远处转移无差异。
核心结论
- 在 NRG Oncology RTOG 0617 试验中,IMRT 与较低的严重肺炎发生率和较低的心脏剂量相关,支持对局部晚期非小细胞肺癌常规使用 IMRT。
研究设计与样本
- NRG Oncology RTOG 0617 随机临床试验的二次分析,比较 IMRT 与 3D-CRT。
- 患者接受卡铂和紫杉醇同步化疗,联合或不联合西妥昔单抗,放疗剂量为 60 Gy 与 74 Gy。
- 共纳入 482 例患者,53% 接受 3D-CRT,47% 接受 IMRT;中位随访 21.3 个月。
主要发现
- IMRT 组计划治疗体积更大(中位数 427 mL vs 486 mL,P=0.005)。
- IMRT 组计划治疗体积/肺体积比值更大(中位数 0.13 vs 0.15,P=0.013)。
- IMRT 组 IIIB 期疾病更多(30.3% vs 38.6%,P=0.056)。
- 两组 2 年总生存、无进展生存、局部失败及无远处转移生存无差异。
- IMRT 组 ≥3 级肺炎更少(3.5% vs 7.9%,P=0.039),校正分析中风险降低(OR 0.41,95%CI 0.171-0.986,P=0.046)。
关键数值与推荐
- IMRT 组 ≥3 级肺炎发生率 3.5%,3D-CRT 组 7.9%(P=0.039)。
- 校正分析中 IMRT 与 ≥3 级肺炎风险降低相关(OR 0.41,95%CI 0.171-0.986,P=0.046)。
- IMRT 产生较低的心脏剂量(P<0.05)。
- 心脏接受 40 Gy 的体积(V40)在校正分析中与总生存显著相关(P<0.05)。
- 肺 V20 在多变量分析与 ≥3 级肺炎风险增加相关(P=0.026);肺 V5 与任何 ≥3 级毒性无关。
临床怎么用
- 作者结论认为 IMRT 与较低的严重肺炎发生率和较低的心脏剂量相关,支持对局部晚期非小细胞肺癌常规使用 IMRT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Although intensity-modulated radiation therapy (IMRT) is increasingly used to treat locally advanced non-small-cell lung cancer (NSCLC), IMRT and three-dimensional conformal external beam radiation therapy (3D-CRT) have not been compared prospectively. This study compares 3D-CRT and IMRT outcomes for locally advanced NSCLC in a large prospective clinical trial. Patients and Methods A secondary analysis was performed to compare IMRT with 3D-CRT in NRG Oncology clinical trial RTOG 0617, in which patients received concurrent chemotherapy of carboplatin and paclitaxel with or without cetuximab, and 60- versus 74-Gy radiation doses. Comparisons included 2-year overall survival (OS), progression-free survival, local failure, distant metastasis, and selected Common Terminology Criteria for Adverse Events (version 3) ≥ grade 3 toxicities. Results The median follow-up was 21.3 months. Of 482 patients, 53% were treated with 3D-CRT and 47% with IMRT. The IMRT group had larger planning treatment volumes (median, 427 v 486 mL; P = .005); a larger planning treatment volume/volume of lung ratio (median, 0.13 v 0.15; P = .013); and more stage IIIB disease (30.3% v 38.6%, P = .056). Two-year OS, progression-free survival, local failure, and distant metastasis-free survival were not different between IMRT and 3D-CRT. IMRT was associated with less ≥ grade 3 pneumonitis (7.9% v 3.5%, P = .039) and a reduced risk in adjusted analyses (odds ratio, 0.41; 95% CI, 0.171 to 0.986; P = .046). IMRT also produced lower heart doses ( P < .05), and the volume of heart receiving 40 Gy (V40) was significantly associated with OS on adjusted analysis ( P < .05). The lung V5 was not associated with any ≥ grade 3 toxicity, whereas the lung V20 was associated with increased ≥ grade 3 pneumonitis risk on multivariable analysis ( P = .026). Conclusion IMRT was associated with lower rates of severe pneumonitis and cardiac doses in NRG Oncology clinical trial RTOG 0617, which supports routine use of IMRT for locally advanced NSCLC.
引用
- Chun SG, Hu C, Choy H, et al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. 2016. PMID: 28034064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。